N/A
Completed N=56
Effect of NMN Supplementation on Organ System Biology
Source: ClinicalTrials.gov NCT04571008 ↗Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcomePrimary: Change in Muscle Insulin Sensitivity — 19.0; 13.5 (nmol/kg FFM/min) / (µU/mL) — p=0.05
Summary
The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Muscle Insulin Sensitivity |
19.0; 13.5 | 0.05 |
| SECONDARY Changes in Glucose Tolerance |
-9.0; 14 | 0.05 |
Eligibility Criteria
Inclusion Criteria
- BMI 25.0-50.0 kg/m²
- Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.
Exclusion Criteria
- Women who are still having menses
- Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
- Persons who consume moderate-large amounts of caffeine daily (>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
- Unstable weight (>3% change during the last 2 months before entering the study)
Data sourced from ClinicalTrials.gov (NCT04571008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.